KR102833184B1 - 향상된 이중 특이성 폴리펩티드 분자 - Google Patents
향상된 이중 특이성 폴리펩티드 분자 Download PDFInfo
- Publication number
- KR102833184B1 KR102833184B1 KR1020207004219A KR20207004219A KR102833184B1 KR 102833184 B1 KR102833184 B1 KR 102833184B1 KR 1020207004219 A KR1020207004219 A KR 1020207004219A KR 20207004219 A KR20207004219 A KR 20207004219A KR 102833184 B1 KR102833184 B1 KR 102833184B1
- Authority
- KR
- South Korea
- Prior art keywords
- ser
- val
- gly
- leu
- pro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Virology (AREA)
- AIDS & HIV (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762532713P | 2017-07-14 | 2017-07-14 | |
| DE102017115966.5 | 2017-07-14 | ||
| US62/532,713 | 2017-07-14 | ||
| DE102017115966.5A DE102017115966A1 (de) | 2017-07-14 | 2017-07-14 | Polypeptidmolekül mit verbesserter zweifacher Spezifität |
| DE102017119866 | 2017-08-30 | ||
| DE102017119866.0 | 2017-08-30 | ||
| US201862658318P | 2018-04-16 | 2018-04-16 | |
| DE102018108995.3 | 2018-04-16 | ||
| US62/658,318 | 2018-04-16 | ||
| DE102018108995 | 2018-04-16 | ||
| PCT/EP2018/069151 WO2019012138A1 (en) | 2017-07-14 | 2018-07-13 | POLYPEPTIDE MOLECULE WITH IMPROVED DOUBLE-SPECIFICITY |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20200026994A KR20200026994A (ko) | 2020-03-11 |
| KR102833184B1 true KR102833184B1 (ko) | 2025-07-10 |
Family
ID=62951983
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020207004219A Active KR102833184B1 (ko) | 2017-07-14 | 2018-07-13 | 향상된 이중 특이성 폴리펩티드 분자 |
| KR1020207004221A Ceased KR20200026995A (ko) | 2017-07-14 | 2018-07-13 | 향상된 이중 특이성 폴리펩티드 분자 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020207004221A Ceased KR20200026995A (ko) | 2017-07-14 | 2018-07-13 | 향상된 이중 특이성 폴리펩티드 분자 |
Country Status (28)
| Country | Link |
|---|---|
| US (8) | US11905328B2 (enExample) |
| EP (3) | EP3985029A1 (enExample) |
| JP (4) | JP2020530762A (enExample) |
| KR (2) | KR102833184B1 (enExample) |
| CN (2) | CN110914308A (enExample) |
| AU (2) | AU2018298884A1 (enExample) |
| BR (2) | BR112020000769A2 (enExample) |
| CA (2) | CA3069842A1 (enExample) |
| CO (2) | CO2020001029A2 (enExample) |
| CR (2) | CR20200014A (enExample) |
| CY (2) | CY1124091T1 (enExample) |
| DK (2) | DK3428194T3 (enExample) |
| ES (2) | ES2898210T3 (enExample) |
| HR (1) | HRP20211744T1 (enExample) |
| HU (2) | HUE054568T2 (enExample) |
| LT (2) | LT3428194T (enExample) |
| MA (1) | MA46299B1 (enExample) |
| MD (2) | MD3428194T2 (enExample) |
| MX (1) | MX2020011744A (enExample) |
| PE (2) | PE20200615A1 (enExample) |
| PL (2) | PL3652215T3 (enExample) |
| PT (2) | PT3428194T (enExample) |
| RS (2) | RS62544B1 (enExample) |
| SG (2) | SG11202000027WA (enExample) |
| SI (2) | SI3652215T1 (enExample) |
| TW (2) | TWI762677B (enExample) |
| WO (2) | WO2019012138A1 (enExample) |
| ZA (1) | ZA202000842B (enExample) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201604458D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against cancers |
| ES2898210T3 (es) | 2017-07-14 | 2022-03-04 | Immatics Biotechnologies Gmbh | Molécula de polipéptido con especificidad dual mejorada |
| WO2019219709A1 (en) | 2018-05-14 | 2019-11-21 | Immunocore Limited | Bifunctional binding polypeptides |
| GB201904328D0 (en) | 2019-03-28 | 2019-05-15 | Immunocore Ltd | Specific binding molecules |
| PE20220164A1 (es) | 2019-05-27 | 2022-01-28 | Immatics Us Inc | Vectores viricos y uso de los mismos en terapias celulares adoptivas |
| US20210032370A1 (en) * | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
| DE102019121007A1 (de) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Antigenbindende Proteine, die spezifisch an MAGE-A binden |
| CN112409474B (zh) * | 2019-08-23 | 2023-02-28 | 香雪生命科学技术（广东）有限公司 | 一种识别ssx2抗原的高亲和力tcr |
| GB201915282D0 (en) | 2019-10-22 | 2019-12-04 | Immunocore Ltd | Specific binding molecules |
| CN120943967A (zh) * | 2019-12-05 | 2025-11-14 | 艾贝乐医药科技有限公司 | TriAx抗体的组合物及其制备和使用方法 |
| AU2021225817A1 (en) | 2020-02-24 | 2022-10-20 | Immatics US, Inc. | Methods for expanding T cells for the treatment of cancer and related malignancies |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| GB202006629D0 (en) | 2020-05-05 | 2020-06-17 | Immunocore Ltd | Specific binding molecules |
| GB202010329D0 (en) | 2020-07-06 | 2020-08-19 | Immunocore Ltd | Specific binding molecules |
| WO2022040631A1 (en) | 2020-08-21 | 2022-02-24 | Immatics US, Inc. | Methods for isolating cd8+ selected t cells |
| TW202241938A (zh) | 2020-12-31 | 2022-11-01 | 美商英麥提克斯股份有限公司 | Ｃｄ８多肽、組合物及其使用方法 |
| WO2022184805A1 (en) | 2021-03-03 | 2022-09-09 | Immatics Biotechnologies Gmbh | Antigen binding proteins specifically binding sars-cov-2 antigenic peptides in complex with a major histocompatibility complex protein |
| US12435444B2 (en) | 2021-03-09 | 2025-10-07 | Cdr-Life Ag | Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same |
| EP4334361A1 (en) | 2021-05-05 | 2024-03-13 | Immatics Biotechnologies GmbH | Antigen binding proteins specifically binding prame |
| EP4113120A1 (en) | 2021-06-28 | 2023-01-04 | Immatics Biotechnologies GmbH | Method of characterizing the binding characteristics between a peptide of interest and mhc molecules |
| US20230024554A1 (en) | 2021-06-28 | 2023-01-26 | Immatics Biotechnologies Gmbh | Method of characterizing the binding characteristics between a peptide of interest and mhc molecules |
| MX2024001179A (es) | 2021-07-27 | 2024-02-27 | Immatics Biotechnologies Gmbh | Proteinas de union a antigenos que se unen especificamente a ct45. |
| CN117964777A (zh) * | 2021-08-26 | 2024-05-03 | 瑅安生物医药（杭州）有限公司 | 一种接近天然分子的多肽融合分子 |
| TW202332765A (zh) | 2021-09-20 | 2023-08-16 | 美商英麥提克斯股份有限公司 | 用於ｔ細胞療法之ｔ細胞群體的單核球耗盡 |
| US20230190806A1 (en) | 2021-10-06 | 2023-06-22 | Immatics Biotechnologies Gmbh | Methods of treating metastatic lesions and compositions thereof |
| WO2023081461A1 (en) | 2021-11-08 | 2023-05-11 | Immatics US, Inc. | Methods for generating cell spheroids |
| US20230192886A1 (en) | 2021-11-08 | 2023-06-22 | Immatics Biotechnologies Gmbh | Adoptive cell therapy combination treatment and compositions thereof |
| JP2024546875A (ja) * | 2021-12-14 | 2024-12-26 | シーディアール－ライフ・アクチェンゲゼルシャフト | 二連型ｍｈｃ標的化ｔ細胞エンゲージャー |
| EP4479423A1 (en) | 2022-02-20 | 2024-12-25 | Immunocore Limited | Hiv-specific binding molecules and tcr |
| EP4514834A1 (en) | 2022-04-28 | 2025-03-05 | Immatics US, Inc. | Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof |
| JP2025515603A (ja) | 2022-04-28 | 2025-05-20 | イマティクス ユーエス，アイエヌシー． | Ｉｌ－１２ポリペプチド、ｉｌ－１５ポリペプチド、ｉｌ－１８ポリペプチド、ｃｄ８ポリペプチド、それらの組成物、およびそれらの使用方法 |
| JP2025516189A (ja) | 2022-04-28 | 2025-05-27 | イマティクス ユーエス，アイエヌシー． | 膜結合型ｉｌ－１５、ｃｄ８ポリペプチド、細胞、組成物、およびそれらの使用方法 |
| WO2023209124A1 (en) * | 2022-04-29 | 2023-11-02 | Immatics Biotechnologies Gmbh | Mammalian display platform for multispecific antigen binding proteins |
| US20230355678A1 (en) | 2022-05-05 | 2023-11-09 | Immatics US, Inc. | Methods for improving t cell efficacy |
| EP4536836A1 (en) | 2022-06-07 | 2025-04-16 | Regeneron Pharmaceuticals, Inc. | Pseudotyped viral particles for targeting tcr-expressing cells |
| WO2024033332A1 (en) | 2022-08-08 | 2024-02-15 | Immatics Biotechnologies Gmbh | Guided positional scanning method |
| CA3264474A1 (en) | 2022-09-14 | 2024-03-21 | Cdr-Life Ag | MAGE-A4 DOUBLE T LYMPHOCYTE ENGAGEMENT |
| WO2024130179A1 (en) | 2022-12-16 | 2024-06-20 | Repertoire Immune Medicines, Inc. | T cell receptors binding hpv-16 epitopes |
| TW202434641A (zh) | 2023-01-06 | 2024-09-01 | 英商英美偌科有限公司 | 結合分子 |
| CN120584131A (zh) | 2023-01-06 | 2025-09-02 | 英美偌科有限公司 | 针对prame肽-hla复合物的结合分子 |
| WO2025008513A1 (en) | 2023-07-05 | 2025-01-09 | Immatics Biotechnologies Gmbh | A method of identifying mhc-binding proteins and interacting peptides in a sample |
| TW202506719A (zh) | 2023-07-27 | 2025-02-16 | 德商艾瑪提克生物技術有限公司 | 針對mageb2之抗原結合蛋白 |
| WO2025085855A2 (en) * | 2023-10-20 | 2025-04-24 | BioNTech SE | Multispecific t cell engagers compositions and methods of use thereof |
| TW202530269A (zh) * | 2023-10-27 | 2025-08-01 | 大陸商北京可瑞生物科技有限公司 | 基於ｔ細胞受體的多特異性多肽分子及其組合物和用途 |
| WO2025096649A1 (en) | 2023-11-01 | 2025-05-08 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
| WO2025094054A1 (en) * | 2023-11-01 | 2025-05-08 | Immunocore Limited | Method for purifying small multi-domain proteins |
| GB202320012D0 (en) * | 2023-12-22 | 2024-02-07 | Immunocore Ltd | Bispecific molecules |
| WO2025233431A1 (en) | 2024-05-07 | 2025-11-13 | Immatics Biotechnologies Gmbh | Heteromeric proteins comprising three heteromerization improving substitution, production, combinations and applications thereof |
| GB2641580A (en) | 2024-06-07 | 2025-12-10 | T Therapeutics Ltd | Tumour-transforming multispecific proteins |
| CN119529098B (zh) * | 2025-01-22 | 2025-05-30 | 北京可瑞生物科技有限公司 | 对mage-a1具有特异性的结合分子和抗cd3的融合蛋白 |
Family Cites Families (105)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2018248A1 (en) | 1989-06-07 | 1990-12-07 | Clyde W. Shearman | Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use |
| US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
| IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
| US8211422B2 (en) | 1992-03-18 | 2012-07-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric receptor genes and cells transformed therewith |
| PT1231268E (pt) | 1994-01-31 | 2005-11-30 | Univ Boston | Bancos de anticorpos policlonais |
| AU751659B2 (en) | 1997-05-02 | 2002-08-22 | Genentech Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| AU2001270609A1 (en) | 2000-06-30 | 2002-01-14 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Heterodimeric fusion proteins |
| DK1438400T3 (da) | 2001-10-01 | 2009-10-05 | Dyax Corp | Flerkædede eukaryote display-vektorer og anvendelser deraf |
| WO2004033685A1 (en) | 2002-10-09 | 2004-04-22 | Avidex Ltd | Single chain recombinant t cell receptors |
| EP2275441B8 (en) | 2005-04-01 | 2016-10-19 | Immunocore Ltd. | High affinity HIV T cell receptors |
| US9284375B2 (en) * | 2005-04-15 | 2016-03-15 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| WO2006113665A2 (en) | 2005-04-15 | 2006-10-26 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| HUE027013T2 (en) | 2005-05-27 | 2016-10-28 | Ospedale San Raffaele Srl | A gene vector containing MI-RNA |
| AT503861B1 (de) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von t-zell-rezeptoren |
| WO2008045437A2 (en) | 2006-10-09 | 2008-04-17 | The General Hospital Corporation | Chimeric t-cell receptors and t-cells targeting egfrviii on tumors |
| US20110045007A1 (en) | 2007-05-31 | 2011-02-24 | Genmab A/S | Fusion or linked proteins with extended half life |
| CA2711806A1 (en) | 2008-01-11 | 2009-07-16 | Morphosys Ag | Display vectors and methods and uses thereof |
| EP2258719A1 (en) * | 2009-05-19 | 2010-12-08 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Multiple target T cell receptor |
| EP2483301A1 (en) | 2009-10-01 | 2012-08-08 | The United States Of America, As Represented By The Secretary, Department of Health and Human Services | Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer |
| US10464987B2 (en) | 2009-10-06 | 2019-11-05 | Abbvie Inc. | Human single-chain T cell receptors |
| US20130129723A1 (en) | 2009-12-29 | 2013-05-23 | Emergent Product Development Seattle, Llc | Heterodimer Binding Proteins and Uses Thereof |
| NZ600820A (en) | 2009-12-29 | 2014-12-24 | Emergent Product Dev Seattle | Heterodimer binding proteins and uses thereof |
| WO2011085178A1 (en) | 2010-01-11 | 2011-07-14 | Trustees Of Dartmouth College | Monomeric bi-specific fusion protein |
| GB201004551D0 (en) | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| MX349057B (es) | 2010-11-30 | 2017-07-07 | Chugai Pharmaceutical Co Ltd | Agente terapeutico que induce citotoxicidad. |
| SG10201602159VA (en) | 2011-02-11 | 2016-04-28 | Sloan Kettering Inst Cancer | Hla-restricted, peptide-specific antigen binding proteins |
| US20130078250A1 (en) * | 2011-08-23 | 2013-03-28 | Oliver Ast | Bispecific t cell activating antigen binding molecules |
| UY34317A (es) | 2011-09-12 | 2013-02-28 | Genzyme Corp | Anticuerpo antireceptor de célula T (alfa)/ß |
| HK1211949A1 (en) | 2012-11-30 | 2016-06-03 | 罗切格利卡特公司 | Removal of cancer cells by circulating virus-specific cytotoxic t-cells using cancer cell targeted mhc class i comprising multi-function proteins |
| PT2961771T (pt) | 2013-02-26 | 2020-02-28 | Roche Glycart Ag | Moléculas de ligação ao antigénio biespecíficas para ativação das células t, específicas para cd3 e cea |
| MX2015010843A (es) | 2013-02-26 | 2016-04-04 | Roche Glycart Ag | Moleculas biespecificas de union al antigeno que activan celulas t. |
| PL2968520T3 (pl) * | 2013-03-14 | 2022-01-03 | Macrogenics, Inc. | Dwuspecyficzne cząsteczki, które są immunoreaktywne wobec immunologicznych komórek efektorowych wykazujących ekspresję receptora aktywującego |
| EP3074424B1 (en) | 2013-11-27 | 2025-02-12 | Zymeworks BC Inc. | Bispecific antigen-binding constructs targeting her2 |
| EP3736292B1 (en) | 2013-12-17 | 2024-05-08 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
| EA038530B1 (ru) | 2014-03-25 | 2021-09-10 | БЁРИНГЕР ИНГЕЛЬХАЙМ ЭНИМАЛ ХЕЛТ ЮЭсЭй ИНК. | Иммунологические композиции, включающие ослабленные histophilus somni |
| EP3172231B1 (en) | 2014-07-24 | 2021-05-05 | Bluebird Bio, Inc. | Bcma chimeric antigen receptors |
| AU2015301460B2 (en) | 2014-08-14 | 2021-04-08 | Novartis Ag | Treatment of cancer using GFR alpha-4 chimeric antigen receptor |
| EP2985294A1 (en) | 2014-08-14 | 2016-02-17 | Deutsches Krebsforschungszentrum | Recombinant antibody molecule and its use for target cell restricted T cell activation |
| MX2017006571A (es) * | 2014-11-20 | 2017-09-29 | Hoffmann La Roche | Moleculas de union a antigeno biespecificas activadoras de celulas t. |
| GB201501017D0 (en) | 2014-12-23 | 2015-03-04 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
| GB201423361D0 (en) | 2014-12-30 | 2015-02-11 | Immatics Biotechnologies Gmbh | Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides |
| GB201504502D0 (en) | 2015-03-17 | 2015-04-29 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers |
| WO2016154585A1 (en) | 2015-03-26 | 2016-09-29 | Charles Sentman | Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using |
| GB201505305D0 (en) | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
| GB201505585D0 (en) | 2015-03-31 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers |
| GB201507030D0 (en) | 2015-04-24 | 2015-06-10 | Immatics Biotechnologies Gmbh | Immunotherapy against lung cancers, in particular NSCLC |
| GB201507719D0 (en) | 2015-05-06 | 2015-06-17 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers |
| DK3298033T4 (da) | 2015-05-18 | 2023-10-02 | Tcr2 Therapeutics Inc | Sammensætninger og medicinske anvendelser til tcr-reprogrammering under anvendelse af fusionsproteiner |
| EP3095792A1 (en) | 2015-05-19 | 2016-11-23 | Klinikum rechts der Isar der Technischen Universität München | T cell receptor with specificity for myeloperoxidase peptide and uses thereof |
| GB201510771D0 (en) | 2015-06-19 | 2015-08-05 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer |
| GB201511191D0 (en) | 2015-06-25 | 2015-08-12 | Immatics Biotechnologies Gmbh | T-cell epitopes for the immunotherapy of myeloma |
| GB201511546D0 (en) | 2015-07-01 | 2015-08-12 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| GB201511792D0 (en) | 2015-07-06 | 2015-08-19 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers |
| MY189596A (en) | 2015-07-15 | 2022-02-18 | Immatics Biotechnologies Gmbh | A novel peptides for use in immunotherapy against epithelial ovarian cancer and other cancers |
| GB201513921D0 (en) | 2015-08-05 | 2015-09-23 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
| GB201515321D0 (en) | 2015-08-28 | 2015-10-14 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers |
| US10130693B2 (en) | 2015-08-28 | 2018-11-20 | Immatics Biotechnologies Gmbh | Peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers |
| GB201517538D0 (en) | 2015-10-05 | 2015-11-18 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers |
| WO2017059900A1 (en) | 2015-10-07 | 2017-04-13 | Biontech Cell & Gene Therapies Gmbh | Antigen receptors and uses thereof |
| MA45004A (fr) | 2015-10-09 | 2019-03-27 | Immatics Biotechnologies Gmbh | Anticorps spécifiques anti-wt1-hla |
| RU2767209C2 (ru) * | 2015-10-23 | 2022-03-16 | Еурека Терапьютикс, Инк. | Химерные конструкции антитело/т-клеточный рецептор и их применения |
| GB201521746D0 (en) | 2015-12-10 | 2016-01-27 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers |
| GB201521894D0 (en) | 2015-12-11 | 2016-01-27 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against various cancers |
| GB201522667D0 (en) | 2015-12-22 | 2016-02-03 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers |
| GB201522592D0 (en) * | 2015-12-22 | 2016-02-03 | Immunocore Ltd | T cell receptors |
| GB201602918D0 (en) | 2016-02-19 | 2016-04-06 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers |
| GB201603568D0 (en) | 2016-03-01 | 2016-04-13 | Immatics Biotechnologies Gmbh | Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer |
| GB201603987D0 (en) | 2016-03-08 | 2016-04-20 | Immatics Biotechnologies Gmbh | Uterine cancer treatments |
| CN114634569B (zh) | 2016-04-15 | 2024-08-20 | 达特茅斯大学理事会 | 高亲和力b7-h6抗体和抗体片段 |
| JP6989138B2 (ja) | 2016-06-17 | 2022-01-05 | メディジーン イミュノテラピーズ ゲーエムベーハー | Ｔ細胞受容体及びその使用 |
| WO2018005447A1 (en) | 2016-06-27 | 2018-01-04 | The Procter & Gamble Company | Apparatus and method for assessing tooth-sensitivity treatment by oral-care product |
| JP7109789B2 (ja) | 2016-08-02 | 2022-08-01 | ティーシーアール２ セラピューティクス インク． | 融合タンパク質を使用したｔｃｒの再プログラム化のための組成物及び方法 |
| JP7012364B2 (ja) | 2016-08-05 | 2022-02-14 | 国立大学法人東北大学 | Ｔ細胞受容体の認識機構を用いたがん又は感染症の治療及び診断 |
| WO2018050902A2 (en) | 2016-09-15 | 2018-03-22 | Quadrucept Bio Limited | Multimers, tetramers & octamers |
| CN106831996B (zh) * | 2017-03-31 | 2020-05-19 | 北京智仁美博生物科技有限公司 | 具有cd3e和/或her2靶向功能的双特异性抗体及其用途 |
| KR102724621B1 (ko) | 2017-06-01 | 2024-11-01 | 우니베르지테트 스튜트가르트 | 이종이량체화 Ig 도메인 |
| ES2898210T3 (es) | 2017-07-14 | 2022-03-04 | Immatics Biotechnologies Gmbh | Molécula de polipéptido con especificidad dual mejorada |
| US20200261502A1 (en) | 2017-09-08 | 2020-08-20 | Carsgen Therapeutics Co., Ltd. | Genetically engineered t cell and application thereof |
| WO2019151392A1 (ja) | 2018-01-31 | 2019-08-08 | 国立大学法人東北大学 | 抗原特異的ｍｈｃ発現調節法 |
| WO2019219709A1 (en) | 2018-05-14 | 2019-11-21 | Immunocore Limited | Bifunctional binding polypeptides |
| EA202091977A1 (ru) | 2018-05-28 | 2021-02-09 | Драгонфлай Терапьютикс, Инк. | Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения |
| US20220275043A1 (en) | 2018-07-17 | 2022-09-01 | Massachusetts Institute Of Technology | Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof |
| WO2020057610A1 (en) | 2018-09-20 | 2020-03-26 | Wuxi Biologics (Shanghai) Co., Ltd. | Novel bispecific anti-ctla-4/pd-1 polypeptide complexes |
| GB201903767D0 (en) | 2019-03-19 | 2019-05-01 | Quadrucept Bio Ltd | Multimers, tetramers & octamers |
| GB201906685D0 (en) | 2019-05-13 | 2019-06-26 | Ultrahuman Six Ltd | Activatable protein constructs and uses thereof |
| CA3146845A1 (en) | 2019-07-15 | 2021-01-21 | Neogene Therapeutics B.V. | Method to isolate tcr genes |
| US20210032370A1 (en) * | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
| DE102019121007A1 (de) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Antigenbindende Proteine, die spezifisch an MAGE-A binden |
| US20220306720A1 (en) | 2019-09-06 | 2022-09-29 | Eli Lilly And Company | Proteins comprising t-cell receptor constant domains |
| WO2021058807A1 (en) | 2019-09-25 | 2021-04-01 | Universität Stuttgart | Trivalent binding molecules |
| CN114787186B (zh) | 2019-09-27 | 2025-06-03 | 艾吉纳斯公司 | 异二聚体蛋白 |
| KR20220098379A (ko) | 2019-11-15 | 2022-07-12 | 그릿스톤 바이오, 인코포레이티드 | 공유 네오항원을 표적으로 하는 항원-결합 단백질 |
| CU20220029A7 (es) | 2019-11-18 | 2023-01-16 | BioNTech SE | Receptores de tcr de prame |
| EP4077370A4 (en) | 2019-12-17 | 2024-02-28 | The Johns Hopkins University | MANA BODY TARGETING TUMOR ANTIGENS AND METHODS OF USE |
| CN110964122B (zh) | 2019-12-24 | 2022-04-15 | 南京北恒生物科技有限公司 | T细胞受体融合蛋白及其用途 |
| US20230130925A1 (en) | 2020-03-16 | 2023-04-27 | University Of Southern California | Methods to prevent, ameliorate and treat complications from viral infections |
| AU2021237570A1 (en) | 2020-03-16 | 2022-09-08 | Angeles Therapeutics, Inc. | Novel antigen binding domains and synthetic antigen receptors incorporating the same |
| WO2021222576A1 (en) | 2020-05-01 | 2021-11-04 | A2 Biotherapeutics, Inc. | Pag1 fusion proteins and methods of making and using same |
| AU2021289612A1 (en) | 2020-06-10 | 2023-01-19 | The University Of Melbourne | HIV-1 antibodies |
| WO2022026358A1 (en) | 2020-07-27 | 2022-02-03 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Multifunctional immunoglobulin-fold polypeptides from alternative translational initiation and termination |
| US20230374140A1 (en) | 2020-10-09 | 2023-11-23 | Memorial Sloan Kettering Cancer Center | Compositions targeting ndc80/mhc complexes and uses thereof |
| WO2022083668A1 (en) | 2020-10-21 | 2022-04-28 | Nanjing Legend Biotech Co., Ltd. | Use of a chimeric co-stimulatory receptor for cell therapy |
| CA3167637A1 (en) | 2020-12-21 | 2022-06-30 | Eric Escobar-Cabrera | Stabilized tcr constructs and methods of use |
| CA3208717A1 (en) | 2021-02-19 | 2022-08-25 | Preet M. Chaudhary | Single-chain and multi-chain synthetic antigen receptors for diverse immune cells |
-
2018
- 2018-07-13 ES ES18183508T patent/ES2898210T3/es active Active
- 2018-07-13 PL PL18740829T patent/PL3652215T3/pl unknown
- 2018-07-13 DK DK18183508.3T patent/DK3428194T3/da active
- 2018-07-13 EP EP21191794.3A patent/EP3985029A1/en active Pending
- 2018-07-13 HR HRP20211744TT patent/HRP20211744T1/hr unknown
- 2018-07-13 WO PCT/EP2018/069151 patent/WO2019012138A1/en not_active Ceased
- 2018-07-13 KR KR1020207004219A patent/KR102833184B1/ko active Active
- 2018-07-13 MD MDE20190844T patent/MD3428194T2/ro unknown
- 2018-07-13 US US16/035,403 patent/US11905328B2/en active Active
- 2018-07-13 SG SG11202000027WA patent/SG11202000027WA/en unknown
- 2018-07-13 LT LTEP18183508.3T patent/LT3428194T/lt unknown
- 2018-07-13 US US16/035,429 patent/US20190016804A1/en not_active Abandoned
- 2018-07-13 PT PT181835083T patent/PT3428194T/pt unknown
- 2018-07-13 PE PE2020000058A patent/PE20200615A1/es unknown
- 2018-07-13 ES ES18740829T patent/ES2871146T3/es active Active
- 2018-07-13 CR CR20200014A patent/CR20200014A/es unknown
- 2018-07-13 SG SG11202000025SA patent/SG11202000025SA/en unknown
- 2018-07-13 US US16/035,412 patent/US20190016802A1/en not_active Abandoned
- 2018-07-13 CA CA3069842A patent/CA3069842A1/en active Pending
- 2018-07-13 RS RS20211381A patent/RS62544B1/sr unknown
- 2018-07-13 CR CR20200013A patent/CR20200013A/es unknown
- 2018-07-13 EP EP18740829.9A patent/EP3652215B1/en active Active
- 2018-07-13 CN CN201880046726.5A patent/CN110914308A/zh active Pending
- 2018-07-13 BR BR112020000769-2A patent/BR112020000769A2/pt not_active Application Discontinuation
- 2018-07-13 MD MDE20200533T patent/MD3652215T2/ro unknown
- 2018-07-13 LT LTEP18740829.9T patent/LT3652215T/lt unknown
- 2018-07-13 DK DK18740829.9T patent/DK3652215T3/da active
- 2018-07-13 BR BR112020000762-5A patent/BR112020000762A2/pt unknown
- 2018-07-13 AU AU2018298884A patent/AU2018298884A1/en not_active Abandoned
- 2018-07-13 US US16/035,420 patent/US20190016803A1/en not_active Abandoned
- 2018-07-13 RS RS20210561A patent/RS61817B1/sr unknown
- 2018-07-13 HU HUE18740829A patent/HUE054568T2/hu unknown
- 2018-07-13 SI SI201830285T patent/SI3652215T1/sl unknown
- 2018-07-13 CA CA3069610A patent/CA3069610A1/en active Pending
- 2018-07-13 EP EP18183508.3A patent/EP3428194B1/en active Active
- 2018-07-13 PE PE2020000056A patent/PE20200614A1/es unknown
- 2018-07-13 CN CN201880046721.2A patent/CN110914307A/zh active Pending
- 2018-07-13 KR KR1020207004221A patent/KR20200026995A/ko not_active Ceased
- 2018-07-13 PT PT187408299T patent/PT3652215T/pt unknown
- 2018-07-13 HU HUE18183508A patent/HUE057110T2/hu unknown
- 2018-07-13 MA MA46299A patent/MA46299B1/fr unknown
- 2018-07-13 AU AU2018298881A patent/AU2018298881B2/en active Active
- 2018-07-13 WO PCT/EP2018/069157 patent/WO2019012141A1/en not_active Ceased
- 2018-07-13 JP JP2020501174A patent/JP2020530762A/ja active Pending
- 2018-07-13 SI SI201830456T patent/SI3428194T1/sl unknown
- 2018-07-13 PL PL18183508T patent/PL3428194T3/pl unknown
- 2018-07-16 TW TW107124492A patent/TWI762677B/zh not_active IP Right Cessation
- 2018-07-16 TW TW110149543A patent/TWI817302B/zh not_active IP Right Cessation
- 2018-07-17 JP JP2018134424A patent/JP6784724B2/ja active Active
-
2020
- 2020-01-14 MX MX2020011744A patent/MX2020011744A/es unknown
- 2020-01-28 CO CONC2020/0001029A patent/CO2020001029A2/es unknown
- 2020-02-10 ZA ZA2020/00842A patent/ZA202000842B/en unknown
- 2020-02-11 CO CONC2020/0001491A patent/CO2020001491A2/es unknown
-
2021
- 2021-05-06 CY CY20211100387T patent/CY1124091T1/el unknown
- 2021-11-01 CY CY20211100934T patent/CY1124835T1/el unknown
-
2022
- 2022-03-03 US US17/686,358 patent/US20220185888A1/en not_active Abandoned
- 2022-03-12 US US17/693,323 patent/US20220195044A1/en not_active Abandoned
-
2023
- 2023-05-22 JP JP2023083663A patent/JP2023103451A/ja active Pending
- 2023-06-08 US US18/331,556 patent/US20230348598A1/en active Pending
- 2023-11-24 JP JP2023198791A patent/JP2024023385A/ja active Pending
-
2025
- 2025-06-17 US US19/240,392 patent/US20250361300A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102833184B1 (ko) | 향상된 이중 특이성 폴리펩티드 분자 | |
| HK40071054A (en) | Improved dual specificity polypeptide molecule | |
| HK40003407B (en) | Improved dual specificity polypeptide molecule | |
| HK40003407A (en) | Improved dual specificity polypeptide molecule | |
| JP2021019626A (ja) | 改善された二重特異性ポリペプチド分子 | |
| HK40029654A (en) | Improved dual specificity polypeptide molecule | |
| HK40029654B (en) | Improved dual specificity polypeptide molecule | |
| EA043129B1 (ru) | Усовершенствованная молекула полипептида с двойной специфичностью | |
| EA043319B1 (ru) | Усовершенствованная молекула полипептида с двойной специфичностью |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| F11 | Ip right granted following substantive examination |
Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| U12 | Designation fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE) Year of fee payment: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| Q13 | Ip right document published |
Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE) |